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ObituaryHans Thoenen: A TributeHans Thoenen: 1928–2012Hans Thoenen passed away on June 23,
2012, a fewmonths after being diagnosed
with lung cancer. He left us grateful for
what he had been able to accomplish in
his life as scientist, but he was neither
exuberant nor proud. Hans remained
extraordinarily modest about his achieve-
ments—he felt far more comfortable
by understating his contributions and
never liked receiving compliments from
colleagues he did not know well. Given
the choice, he preferred to have critics
than adulators around him. ‘‘At least the
former are honest,’’ he would say. Loyalty
was probably the quality Hans valued
most in his interactions with others. He
also was a realist, and when we both
talked about his approaching death, his
only regret was to leave his dear wife
Sonja alone as he felt she may still need
him. Hans knew well that without Sonja’s
support, life as a scientist and group
leader would have been much more
difficult for him.
Hans was born in Zweisimmen, a beau-
tiful village located in the so-called Berner
Oberland, just north of the French
linguistic border. This was one of very
few borders that Hans seemed to
have had some respect for, and even
this was surprising with Hans, as Swiss
Germans are typically remarkable poly-
glots. The Swiss Alps made a great and
lasting impression on him: strong
feelings for freedom and independence
characterize alpine dwellers, which
may explain Hans’s lack of readiness
to compromise on anything, including
in his interactions with colleagues or
journal editors. During the early part of
his life, he was a passionate mountain
climber. His expeditions were not
limited to the Alps; his tours also took
him to far off places, such as the
Peruvian Andes. This attraction for
adventurous undertakings explains his
later passion for research and the
riskier a project was, the more Hans
liked it. One of his most striking traits
was that he was fearless, especially
with regard to the use new technolo-
gies, a key to his scientific endeavors,
which he summarized in a recent auto-biography (http://www.sfn.org/skins/main/
pdf/history_of_neuroscience/hon_vol_6/
c14.pdf). Incidentally, I found it surprising—
but very fortunate—that Hans accepted
to write this piece after an invitation from
Larry Squire. He was apparently given
unrestricted space to detail the many
steps of his scientific trajectory and,
remarkably, this piece seems not to have
been edited much at all, so that posterity
will still be able to enjoy Hans’s voice
‘‘a` l’authentique.’’
While the scientific community is
presumably most familiar with Hans’s
achievements in the field of neurotrophic
factors, fewer may know that his first
scientific big bang came in the late
1960s, with the accidental discovery of
6-hydroxydopamine as a drug that could
selectively kill noradrenergic terminals. In
close collaboration with a dear colleague
of his, Jean-Pierre Tranzer at Roche in
Basel, they discovered through the use
of electron microscopy that this drug
selectively destroys sympathetic nerve
endings. They suggested that 6-hydroxy-
dopamine is taken up by these terminalsNeuron 75where it readily oxidizes, with its killing
specificity ultimately explained by the
high local concentrations created by
the dopamine transporter. Hans’s desire
to further explore the mechanisms of
action of 6-hydroxydopamine using bio-
chemical markers led him to join the
laboratory of Julius Axelrod at the NIH.
While of short duration, this stay had a
profound impact on Hans. First, because
of the discovery of transsynaptic induc-
tion (see below) and second because of
the way science was done in the Axelrod
laboratory. The lack of hierarchy, the
openness for unexpected discoveries
that others would perhaps reject as a
nuisance slowing the confirmation of pre-
conceived ideas, the unusual career path
of Axelrod, including his PhD late in life,
all this was interpreted by Hans as indica-
tions that, after all, there might be room
in Academia not only for adventure,
but also for scientists with unconven-
tional trajectories. Long after leaving the
Axelrod laboratory, Hans would often
talk fondly about ‘‘Julie,’’ as he would
invariably say. As Hans describes in his
autobiography, the discovery of trans-
synaptic induction was an entirely
unexpected consequence of the use
of 6-hydroxydopamine. Together with
Axelrod and Mu¨ller, Hans showed in a
series of short but remarkable publica-
tions in 1969 that increased presyn-
aptic activity leads to elevated levels
of enzyme activity, which they illus-
trated with tyrosine hydroxylase. While
neither antibodies nor RNA probes
were available at the time to directly
quantify the levels of tyrosine hydroxy-
lase, this work showed that increased
enzyme activity necessitates ongoing
transcription and translation, a conclu-
sion that was at the time quite inno-
vative with respect to how electric
signals impact gene expression. Upon
his return to Europe, Hans found it
initially more difficult to publish in highly
regarded journals and for years, when
he would run out of patience with
journal editors—and this would typi-
cally happen quite rapidly—he would
often use the argument that, after all,, August 23, 2012 ª2012 Elsevier Inc. 553
Neuron
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Alps, unfamiliar with the sophisticated
formulations that people learn by default
(he thought) when brought up in large
U.S. cities.
Upon his return from the NIH, Hans
spent a few years again in Basel, where
he was appointed University Professor.
Here, in close collaboration with Martin
Schwab, who joined his laboratory at
the Biozentrum, a then newly created
institute that was, and still is, part of the
University of Basel, Hans reported on
the extraordinary (and, again, entirely
unexpected) observation that tetanus
toxin not only is transported retrogradely
from peripheral nerve terminals, like
nerve growth factor, but also enters
the central nervous system by transsy-
naptic transport. This early work again
involved electron microscopy and, in this
case, it was coupled with autoradiog-
raphy. The results and their interpretation
were spectacular, given the lack of knowl-
edge in the field of ligand-mediated inter-
nalization, even outside the nervous
system.
In many ways, the subsequent move of
Hans’s laboratory to Martinsried was very
fortunate. The Max Planck Society, of
which he became a member in 1977,
treated him extraordinarily well, to the
extent that a few years after his move to
Martinsried near Munich, a new institute
was built next to the existing Max
Planck Institute of Biochemistry. As Max
Planck Director, he was largely shielded
from the worries of grant writing, an
exercise that Hans was not good at.
Hans’s impatience toward anyone unable
to immediately understand what he
had in mind, combined with his use of
undiplomatic language when responding
to comments about his intentions, would
have made it exceedingly difficult for
him to successfully compete for grants
large enough to implement his vision of
science. In Martinsried, the support of
the Max Planck Society allowed him to
comfortably accommodate his growing
group and, importantly, to also recruit
several excellent junior scientists as inde-
pendent group leaders. These included
Wieland Huttner, Heinrich Betz, Reinhard
Jahn, the late Werner Risau, and many
others. These energetic and talented
colleagues contributed further to creating
a vibrant as well as challenging atmo-554 Neuron 75, August 23, 2012 ª2012 Elsevsphere. The framework provided by the
Max Planck Society also immensely facil-
itated the pursuit of long-term projects
including the purification and eventual
cloning of molecules of interest such
as brain-derived neurotrophic factor
(BDNF) and ciliary neurotrophic factor
(CNTF). In this latter project, Michael
Sendtner played a critical role as the
exercise went far beyond the mere purifi-
cation and cloning of CNTF, a molecule
that remains most intriguing with regard
to its secretion and relevance in para-
digms involving lesion and neuronal
dysfunction. As almost everything is un-
expected about CNTF, this was a perfect
project to be successfully tackled by
these two creative individuals. The skills
deployed by Michael and Hans in deci-
phering out some of the main aspects of
the pathophysiology of CNTF remain, to
this day, most impressive.
While Hans’s behavior may have sug-
gested otherwise to those who did not
know him well, he actually loved the
chaotic and unpredictable nature of
research and relished the thrill of unex-
pected observations. The discovery of
what became known as BDNF followed
a similar trajectory. Contrary to post hoc
rationale reconstructions of the kind ‘‘it
was clear from the outset that there
must be other factors out there,’’ the
very start of the project was the result of
an accidental observation linked with
failed attempts to detect nerve growth
factor (NGF) in sources other than the
adult male mouse submandibular gland.
When I joined the laboratory at the Bio-
zentrum in Basel, Hans had developed
a strong and deep interest in NGF and
he warned me that essentially all pub-
lished results related to its distribution
and quantification in tissues or condi-
tioned media were artifactual, resulting
from misinterpreted radioimmunoassay
and bioassay determinations. In his
autobiography, Hans gives me credit
for something he actually figured out
himself, presumably a reflection of his
exceptional generosity. In any event,
because I often questioned Hans’s
sweeping statements, I wanted to check
for myself in the glioma cell-conditioned
media whether NGF would account for
the biological activities reported by
others. By that time, I had learned from
Hans’s wonderful colleague Kitaru Suda,ier Inc.a Japanese chemical engineer, how to
reliably detect NGF. I received a sample
from my friend Ron Lindsay, then working
with C6 glioma cells in the group of Denis
Monard at the Friedrich Miescher Institute
across the Rhine River. Hans turned out
to be right in this case and, using the
techniques available at the time, there
was no detectable NGF activity in this
conditioned medium. Quite unexpect-
edly, there was something else that could
readily be distinguished from NGF by
simple criteria. Retrospectively, I doubt
whether this activity had anything to
do with BDNF but, much inspired by
discussions with David Edgar in Hans’s
laboratory, I thought it would be safer to
use a real tissue as a source to charac-
terize this potentially novel neurotrophic
activity and went ahead using brain
extracts. The unfailing, very active, and
patient support of Hans during the cloning
of BDNF was remarkable, especially in
the face of his proverbial impatience.
This support was all the more important
considering that in the 1980s, there
was a lot of skepticism concerning the
existence of ‘‘factors’’ other than NGF
and later fibroblast growth factor(s) or,
conversely, there was uncritical faith
in the relevance of candidate trophic
molecules such as neuroleukin, sciatin,
purpurin, or pyruvate, as well as many
others.
In short, Hans has been a wonderful
mentor who later also became a close
friend. He was everything but the stereo-
type of the solitary mountaineer. He loved
having guests and many recall countless
festive occasions to which Hans and
his wonderful wife Sonja invited visitors
from abroad and colleagues from the
laboratory. We were spoiled with spec-
tacular dinners while Hans kept filling our
glasses with what seemed to correspond
to much of the yearly production of Swiss
wine. His lack of inhibition in crossing
borders was inspiring, as was his total
lack of understanding for the concept of
political correctness, and I will miss him
for this as well. I feel very privileged
to have met him early, as it was truly
enjoyable to work in an environment in
which everything seemed possible
thanks to Hans and the extraordinarily
generous support provided by the
Max Planck Society over a period of
almost 20 years. Hans was permanently
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and up until age-related retirement in
1996, he felt the constant tension of
fearing that perhaps he did not fully
deserve these privileges. In the rare
moments when he would look back at
his achievements and comment about
them, it was impossible to extract fromhim more than statements like, ‘‘By and
large I think I have done more or less
OK.’’ As close colleagues and friends,
we will do our best to ensure that Sonja
knows how grateful we all are for what
Hans has given us. He died peacefully
and was very grateful for having been
in a position to lead an independent,Neuron 75adventurous scientific life, essentially as
he wanted it to be.
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